Risk factors and outcome of patients with multiple sclerosis from the State of Michoacan Mexico: A case-control study;Factores de riesgo y pronóstico de pacientes con esclerosis múltiple del estado de Michoacán, México: Un estudio de casos y controles

Revista Mexicana de Neurociencia

Volumn 13, Issue 2, 2012, Pages 78-85

  Magaña Zamora, Lucía ^a   Chiquete, Erwin ^a   Campos González, Israel David ^b   Cantú Leal, Raúl ^b   Ibarra Bravo, Octavio ^b   Punzo Bravo, Guillermo ^b   Rojas Flores, Ignacio ^b  

^a INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

^b Hospital General de Morelia Dr Miguel Silva   (Mexico)

Author keywords

Autoimmunity; Immunomodulation; Multiple sclerosis; Outcome

Indexed keywords

AZATHIOPRINE; BETA INTERFERON; STEROID;

ALTERNATIVE MEDICINE; ARTICLE; AUTOIMMUNE DISEASE; CHILD; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE DURATION; EDUCATIONAL STATUS; EXPANDED DISABILITY STATUS SCALE; FAMILY HISTORY; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MAJOR CLINICAL STUDY; MALE; MEXICO; MONOTHERAPY; MULTIPLE SCLEROSIS; OUTCOME ASSESSMENT; PRESCHOOL CHILD; RISK FACTOR; SEX RATIO;

EID: 84861685084     PISSN: 16655044     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, Fujihara K, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 2011; 69: 292-302.
2. Hassan-Smith G, Douglas MR. Management and prognosis of multiple sclerosis. Br J Hosp Med (Lond) 2011; 72: M174-6.
3. Flores-Rivera JJ. Fingolimod: Una novedosa terapia, modulador de los receptores de esfingosina para las formas recurrentes de esclerosis múltiple. Rev Mex Neuroci 2010; 11: 234-9.
4. Alter M, Olivares L. Multiple sclerosis in Mexico. An epidemiologic study. Arch Neurol 1970; 23: 451-9.
5. Rodríguez GA, Sotelo MJ. [Multiple sclerosis in Mexico]. Salud Publica Mex 1981; 23: 451-6.
6. Gonzalez O, Sotelo J. Is the frequency of multiple sclerosis increasing in Mexico? J Neurol Neurosurg Psychiatry 1995; 59: 528-30.
7. Corona T, Rodrigues JL, Otero E, Stopp L. Multiple sclerosis in Mexico: hospital cases at the National Institute of Neurology and Neurosurgery, Mexico City. Neurologia 1996; 11: 170-3.
8. De la Maza M, García J, Bernal J, Fuentes M. [A review of the epidemiology of multiple sclerosis in Mexico]. Rev Neurol 2000; 31: 494-5.
9. Velázquez-Quintana M, Macías-Islas MA, Rivera-Olmos V, Lozano-Zárate J. [Multiple sclerosis in Mexico: a multicentre study]. Rev Neurol 2003; 36: 1019-22.
10. Cordova J, Vargas S, Sotelo J. Western and Asian features of multiple sclerosis in Mexican Mestizos. Clin Neurol Neurosurg 2007; 109: 146-51. (Pubitemid 46073394)
11. Aguirre-Cruz L, Flores-Rivera J, De La Cruz-Aguilera DL, Rangel-López E, Corona T. Multiple sclerosis in Caucasians and Latino Americans. Autoimmunity 2011; 44: 571-5.
12. Noonan CW, Kathman SJ, White MC. Prevalence estimates for MS in the United States and evidence of an increasing trend for women. Neurology 2002; 58: 136-8. (Pubitemid 34041953)
13. Warren SA, Svenson LW, Warren KG. Contribution of incidence to increasing prevalence of multiple sclerosis in Alberta, Canada. Mult Scler 2008; 14: 872-9.
14. Gray OM, McDonnell GV, Hawkins SA. Factors in the rising prevalence of multiple sclerosis in the north-east of Ireland. Mult Scler 2008; 14: 880-6.
15. Bentzen J, Flachs EM, Stenager E, Brønnum-Hansen H, Koch-Henriksen N. Prevalence of multiple sclerosis in Denmark 1950-2005. Mult Scler 2010; 16: 520-5.
16. Ahlgren C, Odén A, Lycke J. High nationwide prevalence of multiple sclerosis in Sweden. Mult Scler 2011; 17: 901-8.
17. Millefiorini E, Cortese A, Di Rezze S, Barletta G, Bellantonio P, Batocchi AP, Di Battista G, et al. The prevalence of multiple sclerosis in central Italy. Mult Scler 2010; 16: 1432-6.
18. Pugliatti M, Sotgiu S, Rosati G. The worldwide prevalence of multiple sclerosis. Clin Neurol Neurosurg 2002; 104: 182-91. (Pubitemid 34792722)
19. Risco J, Maldonado H, Luna L, Osada J, Ruiz P, Juarez A, Vizcarra D. Latitudinal prevalence gradient of multiple sclerosis in Latin America. Mult Scler 2011; 17: 1055-9.
20. Osoegawa M, Kira J, Fukazawa T, Fujihara K, Kikuchi S, Matsui M, et al. Research Committee of Neuroimmunological Diseases. Temporal changes and geographical differences in multiple sclerosis phenotypes in Japanese: nationwide survey results over 30 years. Mult Scler 2009; 15: 159-73.
21. Polman CH, Reingold SC, Edan G, Filippi M, Hartung HP, Kappos L, Lublin FD, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann Neurol 2005; 58: 840-6. (Pubitemid 41746873)
22. Montalban X, Sastre-Garriga J, Filippi M, Khaleeli Z, Téllez N, Vellinga MM, et al. Primary progressive multiple sclerosis diagnostic criteria: a reappraisal. Mult Scler 2009; 15: 1459-65.
23. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS). Neurology 1983; 33: 1444-52. (Pubitemid 14237132)
24. Koch M, Kingwell E, Rieckmann P, Tremlett H. The natural history of primary progressive multiple sclerosis. Neurology 2009; 73: 1996-2002.
25. Koch M, Kingwell E, Rieckmann P, Tremlett H; UBC MS Clinic Neurologists. The natural history of secondary progressive multiple sclerosis. J Neurol Neurosurg Psychiatry 2010; 81: 1039-43.
26. Williamson DM, Marrie RA, Ashley-Koch A, Schiffer R, Trottier J, Wagner L. Design, methodological issues and participation in a multiple sclerosis case-control study. Acta Neurol Scand 2011 [Epub ahead of print].
27. Weinstock-Guttman B, Ramanathan M. Multiple sclerosis in 2011: Advances in therapy, imaging and risk factors in MS. Nat Rev Neurol 2012; 8: 66-8.
28. Ordoñez G, Martinez-Palomo A, Corona T, Pineda B, Flores-Rivera J, Gonzalez A, Chavez-Munguia B, et al. Varicella zoster virus in progressive forms of multiple sclerosis. Clin Neurol Neurosurg 2010; 112: 653-7.
29. Sotelo J, Martínez-Palomo A, Ordoñez G, Pineda B. Varicella-zoster virus in cerebrospinal fluid at relapses of multiple sclerosis. Ann Neurol 2008; 63: 303-11. (Pubitemid 351506349)
30. Burgoon MP, Cohrs RJ, Bennett JL, Anderson SW, Ritchie AM, Cepok S, Hemmer B, et al. Varicella zoster virus is not a disease-relevant antigen in multiple sclerosis. Ann Neurol 2009; 65: 474-9.
31. Gilden DH. Is varicella zoster virus really involved in the pathogenesis of multiple sclerosis? Ann Neurol 2008; 63: 269-71. (Pubitemid 351499856)
32. Maya R, Gershwin ME, Shoenfeld Y. Hepatitis B virus (HBV) and autoimmune disease. Clin Rev Allergy Immunol 2008; 34: 85-102.
33. Balinska MA. Hepatitis B vaccination and French Society ten years after the suspension of the vaccination campaign: how should we raise infant immunization coverage rates? J Clin Virol 2009; 46: 202-5.
34. DeStefano F, Verstraeten T, Jackson LA, Okoro CA, Benson P, Black SB, Shinefield HR, et al. Vaccine Safety Datalink Research Group, National Immunization Program, Centers for Disease Control and Prevention. Vaccinations and risk of central nervous system demyelinating diseases in adults. Arch Neurol 2003; 60: 504-9.
35. Jafari N, Hintzen RQ. The association between cigarette smoking and multiple sclerosis. J Neurol Sci 2011; 311: 78-85.
36. Alonso A, Cook SD, Maghzi AH, Divani AA. A case-control study of risk factors for multiple sclerosis in Iran. Mult Scler 2011; 17: 550-5.